Routine

Secondary prevention after myocardial infarction

Post-MI long-term care · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

After an MI, aggressive risk-factor modification and guideline-directed pharmacotherapy substantially reduce recurrent events and mortality. Dual antiplatelet therapy, high-intensity statin, an ACE inhibitor and a beta-blocker form the core, individualised by LV function and bleeding risk.

Red flags

  • Recurrent chest pain or dynamic ECG changes
  • New or worsening heart failure symptoms
  • Syncope or sustained palpitations (arrhythmia)
  • Bleeding on DAPT
  • LDL-C persistently above target despite adherence

Assessment

Differential diagnosis

  • Recurrent angina / ischaemia
  • Stent restenosis or thrombosis
  • Post-MI heart failure
  • Pericarditis (Dressler)
  • Non-cardiac chest pain
  • Anxiety-related symptoms

Investigations

  • Lipid profile (target LDL-C <1.4 mmol/L / <55 mg/dL)
  • Repeat TTE to document LV function at 6-12 weeks
  • HbA1c and fasting glucose
  • Renal function and electrolytes
  • Resting ECG for Q waves/arrhythmia
  • Consider ambulatory monitoring if arrhythmia suspected

Management

  • Confirm the infarct type and revascularisation status to set DAPT duration
  • Start dual antiplatelet therapy: aspirin plus a P2Y12 inhibitor, typically for 12 months
  • Prescribe a high-intensity statin and titrate to LDL-C target, adding ezetimibe then PCSK9 inhibitor if needed
  • Start an ACE inhibitor (or ARB) for all, especially with reduced EF, hypertension or diabetes
  • Start a beta-blocker, particularly if LVEF reduced or ongoing ischaemia
  • Add an MRA if LVEF ≤40% with heart failure or diabetes
  • Consider an SGLT2 inhibitor if LVEF reduced or diabetes present
  • Enrol in cardiac rehabilitation and structured exercise
  • Address smoking cessation, diet, weight, alcohol and psychosocial support
  • Shorten or modify DAPT in high bleeding risk; extend selectively in high ischaemic risk
  • Review ICD candidacy if LVEF ≤35% persists ≥40 days post-MI despite optimal therapy
  • Arrange planned follow-up to reinforce adherence and re-measure LDL-C

Drugs & doses

Aspirin 75-100 mg PO OD indefinitely
Ticagrelor 90 mg PO BD (or prasugrel 10 mg OD, or clopidogrel 75 mg OD) for 12 months
Atorvastatin 80 mg PO OD (or rosuvastatin 20-40 mg OD)
Ezetimibe 10 mg PO OD if LDL target not met
Ramipril 2.5-10 mg PO OD titrated
Bisoprolol 2.5-10 mg PO OD titrated
Eplerenone 25-50 mg PO OD if LVEF ≤40% with HF/diabetes
Empagliflozin 10 mg PO OD if reduced EF or diabetes

Disposition

GP and cardiology shared care; cardiac rehabilitation referral. Re-refer for persistent reduced EF (device assessment) or recurrent ischaemia.

Complications & pitfalls

  • Recurrent MI / stent thrombosis
  • Progressive LV dysfunction and heart failure
  • Ventricular arrhythmia and sudden cardiac death
  • Bleeding from antithrombotic therapy
  • Statin intolerance / myopathy

Exam pearls

  • LDL-C target after MI is <1.4 mmol/L and a ≥50% reduction from baseline
  • Do not stop a beta-blocker abruptly; rebound ischaemia can occur
  • Colchicine 0.5 mg daily may reduce recurrent events in selected post-MI patients
  • Reassess LVEF before deciding on primary-prevention ICD — it often recovers
  • Add a PPI with DAPT if GI bleeding risk is high

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.